Niagen Bioscience (NAGE) said Tuesday it partnered with wellness provider OneSpaWorld (OSW) to supply its intravenous cellular vitality treatments to more than 80 onboard medical spas.

The therapy is engineered to elevate target blood levels faster than conventional alternatives while reducing infusion durations by 75% without typical severe adverse reactions, the company said.

The 500-milligram doses are sourced through a US Food and Drug Administration-registered outsourcing facility to align with maritime regulatory requirements, Niagen Bioscience said.

Shares of the company were up over 5% in Tuesday trading.

Price: 4.53, Change: +0.25, Percent Change: +5.84